Hydravex NDC 85477-310

NDC codes

FDA NDC Directory

Product NDC (as listed)85477-310Labeler and product segments. Claims need a package NDC.

Product NDC at billing width85477-0310Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
85477-310-28	85477031028	28 g in 1 TUBE (85477-310-28)Marketed from Apr 1, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Hydravex
Generic name (nonproprietary): hydravex
Active ingredients: Hydrocortisone — 2 g/100g
Dosage form: Gel
Route: Topical
Labeler: Oncora Pharma, LLC
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Apr 1, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 85477-310_f4406ba5-e646-40b2-b83a-3b719c985826SPL ID f4406ba5-e646-40b2-b83a-3b719c985826SPL set ID 1da8a263-354a-4ab1-90b4-cc2ecba7c2f6RxCUI 604449UNII WI4X0X7BPJUPC 0854770310285
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N485477031028 followed by a unit qualifier and the quantity

Package 85477-0310-28. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 22, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatosis.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)